8-K: Aethlon Medical Updates Hemopurifier Clinical Progress

Aethlon Medical, Inc. provided an updated corporate presentation highlighting clinical progress of its Hemopurifier device in oncology and infectious diseases, alongside its financial position.

Summary

• Aethlon Medical, Inc. (AEMD) made available an updated corporate presentation on August 20, 2025, detailing the progress of its Hemopurifier blood purification device.
• The Hemopurifier has received two FDA Breakthrough Device designations for advanced/metastatic cancer and life-threatening viral infections without approved therapies.
• Early clinical trials have shown clearance of enveloped viruses and extracellular vesicles (EVs) both in vitro and in patients, with a favorable safety profile observed in 167 Hemopurifier sessions across 41 patients.
• An oncology trial is currently enrolling patients in Australia, with 3 sites open as of February 2025, and 3 participants having received a single Hemopurifier treatment in Cohort 1.
• No dose-limiting toxicities or device-related serious adverse events were reported at 7-day follow-up in the Australian trial, leading to advancement to Cohort 2.
• Pre-clinical research indicates the Hemopurifier's potential in Long COVID, showing greater binding to large EVs in Long COVID patient samples, and in organ transplantation, demonstrating removal of EVs and specific miRNAs from renal perfusates.
• The company reported a cash position of approximately $3.8 million as of June 30, 2025, and maintains a debt-free balance sheet.
• Aethlon's capital structure includes approximately 2.6 million shares outstanding as of August 2025, following a reverse split to maintain Nasdaq listing compliance.
• The company holds a broad patent portfolio, with protection extending to 2044 for some pending applications in the U.S. and internationally.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to promising early clinical safety data, FDA Breakthrough Device designations, a broad patent portfolio, and a debt-free balance sheet. However, the company is still in early clinical stages, faces significant development risks, and has a limited cash runway, which tempers the overall positive outlook.

Positives

• The Hemopurifier has received two FDA Breakthrough Device designations, accelerating its development and review pathway.
• Early clinical trials have demonstrated a favorable safety profile across 167 Hemopurifier sessions in 41 patients.
• The Australian oncology trial has shown no dose-limiting toxicities or device-related serious adverse events in initial cohorts, allowing for progression to next clinical cohorts.
• In vitro experiments demonstrated significant removal (92-99%) of cancer-derived EVs from multiple tumor types and patient plasma.
• The company maintains a debt-free balance sheet, providing financial flexibility.
• Aethlon has successfully maintained its listing on the Nasdaq Capital Market under the ticker AEMD.
• The company benefits from Australia's 43.5% R&D rebate program, supporting capital-efficient clinical development.
• A broad patent portfolio provides long-term competitive advantage, with protection extending to 2044 for some pending applications.

Negatives

• The company's capital structure includes approximately 2.6 million shares outstanding as of August 2025, following a reverse split, which can be a negative signal to investors regarding past share price performance or capital needs.

Risks

• Ability to enroll patients in ongoing and planned clinical trials on a timely basis, or at all.
• Ability to successfully complete clinical trials and achieve the endpoints for the trials, or any future clinical trials with the Hemopurifier.
• Ability to successfully develop and commercialize the Hemopurifier.
• Ability to demonstrate the removal of nanoparticles (NPs), extracellular vesicles (EVs) and their associated cargo with the Hemopurifier.
• The potential synergistic use of the Hemopurifier with chemotherapy, immunotherapy and targeted agents may not be realized.
• Ability to successfully demonstrate the benefit of the Hemopurifier in the organ transplant setting.
• Ability to raise additional capital when needed.
• Ability to maintain listing on the Nasdaq Capital Market.
• Ability to establish and maintain collaborations.
• The timing and success of clinical trials and preclinical research with the Hemopurifier.
• Dependence on CROs and other third parties for clinical trial execution.
• Ability to manufacture Hemopurifiers at scale or cost-effectively.
• Ability to obtain regulatory approvals within the timeframes expected, or at all.
• Complications associated with product development and commercialization activities.
• The size and growth of the market(s) for the Hemopurifier and the rate and degree of market acceptance thereof.
• Ability to attract and retain key management and members of the board of directors.
• Regulatory changes that could impact product development or commercialization.

Future Outlook

The company plans to continue enrolling patients in its Australian oncology trial, with Cohort 2 currently open and Cohort 3 to follow. Upcoming data includes central lab results on EV removal and anti-tumor CD8 T cell changes from the first cohort. Management intends to review and interpret lab findings, present data to regulatory agencies in a pre-PMA meeting, and engage potential partners. Pre-clinical research continues for Long COVID, with next steps focused on EV cargo analysis for mediators of pathogenesis, and further investigation into platelet-derived microparticles and organ transplantation applications.

Management Comments

• We believe the Aethlon Hemopurifier is uniquely positioned as an early treatment option for future bioattacks or pandemic threats, given its ability to target mannose structures on enveloped viruses and its demonstrated removal of enveloped viruses and extracellular vesicles.
• We believe our market capitalization reflects a significant discount to the company's technology, platform, and clinical opportunities.

Industry Context

The Hemopurifier is positioned to address significant unmet needs in the large and growing immunotherapy market, particularly for the 60-70% of cancer patients who do not respond to anti-PD-1 monotherapy. By removing tumor-derived exosomes that contribute to T-cell exhaustion and chemotherapy resistance, the device offers a novel mechanism to potentially enhance immunotherapy responsiveness. In the infectious disease space, the Hemopurifier aims to provide a broad-spectrum early treatment option for emerging viral threats and pandemics, especially enveloped viruses, where delays in developing effective anti-viral therapies and vaccines are common. The company is also exploring applications in Long COVID, a condition with a substantial global incidence and economic burden, and in organ transplantation, where improving outcomes remains a critical area.

Comparison to Industry Standards

• The Hemopurifier targets the 60-70% of cancer patients who do not respond to anti-PD-1 monotherapy, a significant unmet need given the ~$62 billion PD-1/PD-L1 inhibitor market in 2025 (projected to reach ~$120 billion by 2030).
• The device's mechanism of removing tumor-derived exosomes that lead to T cell exhaustion offers a novel approach compared to existing antibody-based treatments like Keytruda and Opdivo, which are PD-1 antibody therapies.
• In organ transplantation, the Hemopurifier's potential to be 'bolted on' to existing Machine Perfusion (MP) platforms aims to further improve outcomes, addressing issues like delayed graft function and acute rejection associated with EV and miRNA release during MP.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if clinical trials demonstrate efficacy and lead to commercialization, but also exposure to high clinical development risks and potential dilution from future capital raises.
• **Patients:** Potential for novel treatment options for advanced cancers, life-threatening viral infections, Long COVID, and improved outcomes in organ transplantation.
• **Employees:** Continued employment and potential growth opportunities as the company progresses through clinical development and potential commercialization.
• **Regulatory Authorities:** Ongoing engagement through Breakthrough Device designations and pre-PMA meetings, requiring adherence to regulatory standards.

Next Steps

• Review and interpret central lab findings from the first cohort of the Australian oncology trial.
• Present data to regulatory agencies in a pre-PMA (Premarket Approval) meeting.
• Engage potential partners for collaboration.
• Continue enrollment in Cohort 2 of the Australian oncology trial (2 Hemopurifier treatments during a 1-week period).
• Open Cohort 3 for enrollment (3 Hemopurifier treatments during a 1-week period) following Cohort 2.
• Conduct EV Cargo Analysis for Mediators of Long COVID Pathogenesis (e.g., viral persistence, HHV reactivation, immune/coagulation dysregulation, T cell exhaustion).

Key Dates

Recommendation

Aethlon Medical presents a promising, patented technology with FDA Breakthrough Device designations and early positive safety data in its Australian oncology trial. The Hemopurifier addresses significant unmet needs in oncology (immunotherapy non-responders) and infectious diseases, with broad potential. However, the company is still in early clinical stages, faces substantial risks inherent in clinical development, and has a limited cash runway of approximately $3.8 million as of June 30, 2025. While the Nasdaq listing is maintained, the recent reverse split indicates past challenges. The investment is highly speculative, warranting a 'hold' for existing investors to monitor upcoming clinical data, and a cautious approach for new investors until further efficacy milestones are achieved.

Keywords

Aethlon Medical, Hemopurifier, oncology, infectious disease, cancer, extracellular vesicles, exosomes, blood purification, medical device, clinical trials, FDA Breakthrough Device, Long COVID, organ transplantation, viral infections, immunotherapy